{'52WeekChange': -0.5818584,
 'SandP52WeekChange': 0.0644362,
 'address1': '35 Parkwood Drive',
 'address2': 'Suite 210',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.9,
 'askSize': 3200,
 'averageDailyVolume10Day': 110450,
 'averageVolume': 98917,
 'averageVolume10days': 110450,
 'beta': 1.249018,
 'beta3Year': None,
 'bid': 1.82,
 'bidSize': 800,
 'bookValue': 1.705,
 'category': None,
 'circulatingSupply': None,
 'city': 'Hopkinton',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.9,
 'dayLow': 1.7187,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.218,
 'enterpriseToRevenue': None,
 'enterpriseValue': 7091245,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '508 422 0951',
 'fiftyDayAverage': 1.6005714,
 'fiftyTwoWeekHigh': 5.13,
 'fiftyTwoWeekLow': 0.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14743957,
 'forwardEps': -0.89,
 'forwardPE': -2.1348314,
 'fromCurrency': None,
 'fullTimeEmployees': 30,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.13972999,
 'heldPercentInstitutions': 0.32178003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/springbankpharm.com',
 'longBusinessSummary': 'Spring Bank Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, discovers and develops '
                        'therapeutics for the treatment of a range of cancers '
                        'and inflammatory diseases using its proprietary small '
                        'molecule nucleotide platform. The company is '
                        'developing SB 11285, a next-generation '
                        'immunotherapeutic cyclic dinucleotide for the '
                        'treatment of selected cancers; novel STING antagonist '
                        'compounds for the treatment of autoimmune and '
                        'inflammatory diseases; and novel platform to enable '
                        'the targeted delivery of payload molecules. It has a '
                        'collaboration agreement with with Roche to explore '
                        'the co-administration of SB 11285. The company was '
                        'formerly known as Spring Bank Technologies, Inc. and '
                        'changed its name to Spring Bank Pharmaceuticals, Inc. '
                        'in May 2008. Spring Bank Pharmaceuticals, Inc. was '
                        'founded in 2002 and is headquartered in Hopkinton, '
                        'Massachusetts.',
 'longName': 'Spring Bank Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 32480120,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_108747575',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -27080000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.73,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '508 473 5993',
 'previousClose': 1.73,
 'priceHint': 4,
 'priceToBook': 1.1143695,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.9,
 'regularMarketDayLow': 1.7187,
 'regularMarketOpen': 1.73,
 'regularMarketPreviousClose': 1.73,
 'regularMarketPrice': 1.73,
 'regularMarketVolume': 69113,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17094800,
 'sharesPercentSharesOut': 0.0032,
 'sharesShort': 54565,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 20736,
 'shortName': 'Spring Bank Pharmaceuticals, In',
 'shortPercentOfFloat': 0.0034999999,
 'shortRatio': 0.95,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'SBPH',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.644,
 'twoHundredDayAverage': 1.393928,
 'volume': 69113,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.springbankpharm.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '01748'}